|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Operating activities: | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash flows used in operating activities: | |||||
| Depreciation of property and equipment | |||||
| Unrealized gain from marketable securities | |||||
| Loss on legal settlement | |||||
| Insurance recovery related to legal settlement | |||||
| Interest income and unrealized gains from marketable securities, net | |||||
| Loss on disposal of property and equipment | |||||
| Share-based compensation | |||||
| Inventory | |||||
| Prepaid expenses and other assets | |||||
| Other payables and accrued liabilities | |||||
| Accounts payable and accrued liabilities | |||||
| Change in long-term deposit | |||||
| Insurance recovery related to legal settlement and legal expenses received in cash | |||||
| Legal settlement paid in cash | |||||
| Net cash flows used in operating activities | |||||
| Investing activities: | |||||
| Short-term deposit | |||||
| Purchase of property and equipment | |||||
| Proceeds from maturities of marketable securities | |||||
| Purchase of marketable securities | |||||
| Proceeds from sales of marketable securities | |||||
| Net cash flows (used in) provided by investing activities | |||||
| Financing activities: | |||||
| Issuance of common stock and warrants, net of issuance costs | |||||
| Exercise of options | |||||
| Net cash flows provided by financing activities | |||||
| Increase in cash, cash equivalents and restricted cash | |||||
| Cash, cash equivalents and restricted cash at beginning of year | |||||
| Cash, cash equivalents and restricted cash at ending of year | |||||
| Supplemental disclosure of non-cash investing and financing activities: | |||||
| Cash received from interest | |||||
| Issuance costs not paid | |||||
| Legal settlement settled through issuance of common stock | |||||
| Right-of-use assets obtained in exchange for lease liabilities | |||||
| Accrued bonus settled through grant of stock-option awards | |||||
| Deferred issuance costs | |||||
Loading...